GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (ASX:RAD) » Definitions » Capex-to-Operating-Income

Radiopharm Theranostics (ASX:RAD) Capex-to-Operating-Income : 0.00 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Radiopharm Theranostics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Radiopharm Theranostics's Capital Expenditure for the six months ended in Dec. 2023 was A$0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-24.70 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Radiopharm Theranostics Capex-to-Operating-Income Historical Data

The historical data trend for Radiopharm Theranostics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Capex-to-Operating-Income Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23
Capex-to-Operating-Income
- -

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Capex-to-Operating-Income - - - - -

Competitive Comparison of Radiopharm Theranostics's Capex-to-Operating-Income

For the Biotechnology subindustry, Radiopharm Theranostics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radiopharm Theranostics's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Capex-to-Operating-Income falls into.



Radiopharm Theranostics Capex-to-Operating-Income Calculation

Radiopharm Theranostics's Capex-to-Operating-Income for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.531) / -34.508
=N/A

Radiopharm Theranostics's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -24.702
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Radiopharm Theranostics  (ASX:RAD) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Radiopharm Theranostics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Radiopharm Theranostics (ASX:RAD) Business Description

Traded in Other Exchanges
Address
62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (ASX:RAD) Headlines

No Headlines